Beijing Biostar Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Beijing Biostar Pharmaceuticals's earnings have been declining at an average annual rate of -24.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 37.9% per year.
Key information
-24.2%
Earnings growth rate
-18.2%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 37.9% |
| Return on equity | -26.2% |
| Net Margin | -284.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Biostar Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 67 | -190 | 138 | 127 |
| 31 Dec 22 | 33 | -161 | 151 | 83 |
| 31 Dec 21 | 71 | -278 | 268 | 92 |
| 31 Dec 20 | 0 | -65 | 39 | 36 |
Quality Earnings: 2563 is currently unprofitable.
Growing Profit Margin: 2563 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2563 is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare 2563's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2563 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 2563 has a negative Return on Equity (-26.22%), as it is currently unprofitable.